Trial site
Zentrum fuer klinische Forschung Dr. I. Schoell GmbH
- 14running trials
- 10closed trials
The trials here
What the 24 trials at this site are about, from their registry records.
- Conditions
- Alzheimer disease6 trials
- Depression5 trials
- Migraine4 trials
- Mild cognitive impairment3 trials
- Multiple sclerosis3 trials
- Parkinson disease3 trials
- CIDP (chronic inflammatory demyelinating polyneuropathy)1 trial
- Schizophrenia1 trial
- Phase
- Phase 315 trials
- Phase 26 trials
- Phase 1/21 trial
- Phase 2/31 trial
- Phase 41 trial
- Status
- Completed10 trials
- Active, not recruiting6 trials
- Recruiting5 trials
- Not yet recruiting3 trials
- Lead sponsor
- Boehringer Ingelheim International GmbH2 trials
- Eli Lilly & Co.2 trials
- Hoffmann-La Roche2 trials
- Seaport Therapeutics2 trials
- Zenas BioPharma (USA), LLC2 trials
- and 14 more
Running trials
Not yet recruiting
Active, not recruiting
Recruiting
A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis
Recruiting
A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis
Active, not recruiting
Active, not recruiting
A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
Active, not recruiting
A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
Enrolling by invitation
Recruiting
Recruiting
Recruiting
Recruiting
Active, not recruiting
Active, not recruiting
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
- Depression3 recruiting
- Alzheimer disease2 recruiting
- Multiple sclerosis2 recruiting
- Parkinson disease1 recruiting
Closed trials
Completed
Terminated
A Study of LY3541860 in Adult Participants With Relapsing Multiple Sclerosis
Completed
A Study of Suvecaltamide in Adults With Moderate to Severe Residual Tremor in Parkinson's Disease
Completed
Completed
Completed
A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)
Completed
Completed
Completed
A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine (PIONEER-PEDS1)
Completed
A Trial to Test if Fremanezumab is Effective in Preventing Migraine in Children and Adolescents
Site data: ClinicalTrials.govUpdated 19 Nov 2026